Cited 83 times in
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.date.accessioned | 2014-12-20T17:35:02Z | - |
dc.date.available | 2014-12-20T17:35:02Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94875 | - |
dc.description.abstract | INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed/carboplatin or docetaxel/carboplatin. METHODS: This multicenter, open-label, parallel-group, phase 3 trial comprised patients randomized (1:1) to pemetrexed/carboplatin (n = 128) or docetaxel/carboplatin (n = 132). Patients received treatment on day 1 of each 21-day cycle (maximum of six cycles). Treatment included carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) or docetaxel (75 mg/m(2)). The primary outcome measure, survival without treatment-emergent grade 3/4 toxicity, was defined as the time from randomization to the first treatment-emergent grade 3/4 adverse event or death and was analyzed using a log-rank test. The analysis population included 106 patients in the pemetrexed/carboplatin (Pem/Carb) group and 105 patients in the docetaxel/carboplatin (Doc/Carb) group. RESULTS: Survival without treatment-emergent grade 3/4 toxicity was significantly longer in the Pem/Carb versus the Doc/Carb group (log-rank p < 0.001; median survival without treatment-emergent grade 3/4 toxicity: 3.2 versus 0.7 months; adjusted hazard ratio = 0.45 [95% confidence interval: 0.34-0.61]). Overall survival was similar in the Pem/Carb versus the Doc/Carb group (log-rank p = 0.934; median survival: 14.9 versus 14.7 months; adjusted hazard ratio = 0.93 [95% confidence interval: 0.66-1.32]). Compared with the Doc/Carb group, fewer patients in the Pem/Carb group experienced grade 3/4 drug-related, treatment-emergent neutropenia, leukopenia, or febrile neutropenia, and more patients experienced anemia and thrombocytopenia. There were three study drug-related deaths during treatment in each group. CONCLUSIONS: The favorable benefit-to-risk profile of pemetrexed/carboplatin suggests that pemetrexed/carboplatin is an appropriate first-line treatment option for chemonaïve patients with advanced, nonsquamous non-small cell lung cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1907~1914 | - |
dc.relation.isPartOf | JOURNAL OF THORACIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carcinoma, Large Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Large Cell/mortality | - |
dc.subject.MESH | Carcinoma, Large Cell/pathology | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/mortality | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Glutamates/administration & dosage | - |
dc.subject.MESH | Guanine/administration & dosage | - |
dc.subject.MESH | Guanine/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Pemetrexed | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.title | A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Rodrigues-Pereira, José | - |
dc.contributor.googleauthor | Kim, Joo-Hang | - |
dc.contributor.googleauthor | Magallanes, Manuel | - |
dc.contributor.googleauthor | Lee, Dae Ho | - |
dc.contributor.googleauthor | Wang, Jie | - |
dc.contributor.googleauthor | Ganju, Vinod | - |
dc.contributor.googleauthor | Martínez-Barrera, Luis | - |
dc.contributor.googleauthor | Barraclough, Helen | - |
dc.contributor.googleauthor | van Kooten, Maximiliano | - |
dc.contributor.googleauthor | Orlando, Mauro | - |
dc.identifier.doi | 10.1097/JTO.0b013e318226b5fa | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.relation.journalcode | J01909 | - |
dc.identifier.eissn | 1556-1380 | - |
dc.identifier.pmid | 22005471 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=01243894-201111000-00018&LSLINK=80&D=ovft | - |
dc.subject.keyword | Carboplatin | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | First-line therapy | - |
dc.subject.keyword | Non-small cell lung carcinoma | - |
dc.subject.keyword | Nonsquamous | - |
dc.subject.keyword | Pemetrexed | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 6 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1907 | - |
dc.citation.endPage | 1914 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC ONCOLOGY, Vol.6(11) : 1907-1914, 2011 | - |
dc.identifier.rimsid | 27818 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.